| Assessment Status | Rapid review complete |
| HTA ID | - |
| Drug | Ustekinumab |
| Brand | Stelara® |
| Indication | For the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNF-α antagonist or have medical contraindications to such therapies |
| Assessment Process | |
| Rapid review commissioned | 28/11/2016 |
| Rapid review completed | 11/01/2017 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended at the Submitted Price. |
The HSE has approved reimbursement following confidential price negotiations November 2017
